342017-95-2

Basic information

• Product Name: 6-BROMO-2-(4-BROMO-PHENYL)-QUINOLINE-4-CARBOXYLIC ACID
• Synonyms: AKOS AUF0618;6-BROMO-2-(4-BROMO-PHENYL)-QUINOLINE-4-CARBOXYLIC ACID
• CAS NO: 342017-95-2
• Molecular Formula: C₁₆H₉Br₂NO₂
• Molecular Weight: 407.06
• Mol File: 342017-95-2.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-BROMO-2-(4-BROMO-PHENYL)-QUINOLINE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-2-(4-BROMO-PHENYL)-QUINOLINE-4-CARBOXYLIC ACID(342017-95-2)
• EPA Substance Registry System: 6-BROMO-2-(4-BROMO-PHENYL)-QUINOLINE-4-CARBOXYLIC ACID(342017-95-2)

Safety Data

• Hazardous Substances Data: 342017-95-2(Hazardous Substances Data)

Usage

General Description

6-Bromo-2-(4-bromo-phenyl)-quinoline-4-carboxylic acid is a chemical compound with a quinoline backbone and two bromine substituents. It is a carboxylic acid derivative, which gives it acidic properties and potential for forming salts. 6-BROMO-2-(4-BROMO-PHENYL)-QUINOLINE-4-CARBOXYLIC ACID is used in the pharmaceutical and chemical industries as a starting material for the synthesis of various biologically active compounds. It is also utilized in medicinal chemistry research for its potential as a drug candidate or as a building block in drug discovery. Its unique structure and reactivity make it a valuable intermediate in the synthesis of complex organic molecules.

Upstream product

• 87-48-9 5-Bromo-1H-indole-2,3-dione 
• 99-90-1 para-bromoacetophenone 
• 98-86-2 acetophenone 

Relevant articles and documents

Synthesis, characterization, and antileishmanial activity of certain quinoline-4-carboxylic acids

Leishmaniasis is a fatal neglected parasitic disease caused by protozoa of the genus Leishmania and transmitted to humans by different species of phlebotomine sandflies. The disease incidence continues to increase due to lack of vaccines and prophylactic drugs. Drugs commonly used for the treatment are frequently toxic and highly expensive. The problem of these drugs is further complicated by the development of resistance. Thus, there is an urgent need to develop new antileishmanial drug candidates. The aim of this study was to synthesize certain quinoline-4-carboxylic acids, confirm their chemical structures, and evaluate their antileishmanial activity. Pfitzinger reaction was employed to synthesize fifteen quinoline-4-carboxylic acids (Q1-Q15) by reacting equimolar mixtures of isatin derivatives and appropriate α-methyl ketone. The products were purified, and their respective chemical structures were deduced using various spectral tools (IR, MS, 1H NMR, and 13C NMR). Then, they were investigated against L. donovani promastigote (clinical isolate) in different concentration levels (200 μg/mL to 1.56 μg/mL) against sodium stibogluconate and amphotericin B as positive controls. The IC50 for each compound was determined and manipulated statistically. Among these compounds, Q1 (2-methylquinoline-4-carboxylic acid) was found to be the most active in terms of IC50.